LIVDELZI is the first and only primary biliary cholangitis (PBC) treatment that achieved statistically significant reduction across biochemical response, alkaline phosphatase (ALP) normalization, and pruritus vs placebo.¹

62% of patients achieved the composite biochemical response at month 12¹
1 in 4 patients treated with LIVDELZI normalized their ALP at month 12¹
Rapid improvement in pruritus seen as early as month 1, with a statistically significant difference at month 6; improvements were observed through month 12^1,2

Discover Our Data

Biochemical response was defined as achieving ALP <1.67 x upper limit of normal (ULN), decrease in ALP of ≥15% from baseline, and total bilirubin (TB) ≤ULN.¹

INDICATION AND USAGE

LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

This indication is approved under accelerated approval based on a reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Limitation of use: Use of LIVDELZI is not recommended in patients who have or develop decompensated cirrhosis (eg, ascites, variceal bleeding, hepatic encephalopathy).

Register for more information

Stay up to date with the latest information about LIVDELZI.

Get your appropriate patients started with LIVDELZI

Learn more about patient support resources for LIVDELZI at MySupportPath.com.

Explore Support Path^®

Lower is better with LIVDELZI